<DOC>
	<DOC>NCT01899066</DOC>
	<brief_summary>This study will evaluate the clinical efficacy of intravitreal injections of Ranibizumab (Lucentis) together with chemotherapy in the treatment of Retinoblastoma as compared to chemotherapy alone.</brief_summary>
	<brief_title>Efficacy Study of Lucentis in the Treatment of Retinoblastoma</brief_title>
	<detailed_description>This study will be a phase II open label interventional case series. Patients with retinoblastoma will be randomized to receive chemotherapy with or without intravitreal ranibizumab at a dose of 0.5mg/0.05 ml. Patients will receive ranibizumab via a pars plana injection on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 24 months .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Ability to provide written informed consent and comply with study assessments for the full duration of the study. Definite characteristic signs of retinoblastoma,Group D base on Intraocular International Retinoblastoma classify, IIRC. History of surgical intervention for retinoblastoma in the study eye. Any previous disease in the study eye. Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals). Previous participation in a clinical trial (for either eye) involving anti angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Efficacy</keyword>
</DOC>